We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

SMIN:LSESmiths Group Plc Analysis

Data as of 2026-08-03 - not real-time

£2,642.00

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

Smiths Group plc is trading at 2,642 GBp, comfortably above its 20‑day SMA (2,575) and 50‑day SMA (2,550) while still below the 200‑day SMA (2,503), indicating a sustained bullish bias. The technical suite is supportive – the MACD histogram is positive (≈5.4) and the signal is bullish, while the RSI sits at a neutral 56, suggesting room for upside without immediate overbought pressure. Valuation metrics are mixed: a trailing P/E of 35.7 exceeds the industry average of 30.9, and a P/B of 5.15 signals premium pricing, yet the DCF‑derived fair value of ~835 GBp implies a substantial upside potential, reflected in the model’s 6.7 % upside estimate. The company delivers a modest 1.77 % dividend yield with a payout ratio of 62 %, supported by positive operating cash flow (≈£374 m) despite a sizable negative free cash flow and a debt‑to‑equity of 73 %, which raises leverage concerns. Volatility is elevated at 25.9 % over the past 30 days, but beta is low (≈0.49), tempering systematic risk. Overall, the stock sits near a key resistance around 2,715 GBp, with decreasing volume hinting at a potential short‑term pause, while the “Extreme Greed” sentiment index underscores strong market optimism.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Bullish MACD and SMA alignment supports near‑term stability
  • Price approaching resistance at 2,715 GBp may trigger a pullback
  • Decreasing volume adds uncertainty to immediate moves

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • Forward EPS growth improves valuation (forward P/E ~23)
  • Dividend yield of 1.77 % offers income while earnings recover
  • Modelled upside of ~6.7 % aligns with target median price (~2,835 GBp)

Long Term

> 3 years
Neutral
Model confidence: 5/10

Key Factors

  • Diversified industrial segments provide resilient cash flows
  • High debt‑to‑equity and negative free cash flow pose balance‑sheet risk
  • Elevated valuation multiples may limit long‑run price appreciation

Key Metrics & Analysis

Financial Health

Revenue Growth-1.00%
Profit Margin8.71%
P/E Ratio35.7
ROE12.53%
ROA6.54%
Debt/Equity73.09
P/B Ratio5.2
Op. Cash Flow£374.0M
Free Cash Flow£-778750016
Industry P/E30.9

Technical Analysis

TrendBullish
RSI56.5
Support£2,419.00
Resistance£2,715.00
MA 20£2,575.30
MA 50£2,549.88
MA 200£2,503.39
MACDBullish
VolumeDecreasing
Fear & Greed Index92.88

Valuation

Fair Value£835.33
Target Price£2,819.00
Upside/Downside6.70%
GradeOvervalued
TypeGrowth
Dividend Yield1.77%

Risk Assessment

Beta0.49
Volatility25.88%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.